Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 5.6% in June

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totalling 4,220,000 shares, a drop of 5.6% from the May 31st total of 4,470,000 shares. Based on an average daily trading volume, of 795,400 shares, the days-to-cover ratio is currently 5.3 days. Approximately 7.6% of the company’s stock are short sold.

Agios Pharmaceuticals Stock Down 0.1 %

Agios Pharmaceuticals stock opened at $42.02 on Thursday. The company’s 50 day moving average price is $38.93 and its two-hundred day moving average price is $31.06. Agios Pharmaceuticals has a 52 week low of $19.80 and a 52 week high of $49.06. The stock has a market cap of $2.39 billion, a P/E ratio of -6.65 and a beta of 0.78.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The firm’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.47) EPS. On average, equities analysts anticipate that Agios Pharmaceuticals will post -2.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, June 4th. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 4th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $50.67.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in Agios Pharmaceuticals by 1.2% during the third quarter. Rhumbline Advisers now owns 102,122 shares of the biopharmaceutical company’s stock valued at $2,528,000 after purchasing an additional 1,240 shares in the last quarter. Rock Springs Capital Management LP raised its stake in shares of Agios Pharmaceuticals by 0.9% during the third quarter. Rock Springs Capital Management LP now owns 2,710,061 shares of the biopharmaceutical company’s stock worth $67,074,000 after acquiring an additional 23,894 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Agios Pharmaceuticals by 0.6% in the 3rd quarter. Deutsche Bank AG now owns 581,601 shares of the biopharmaceutical company’s stock worth $14,395,000 after acquiring an additional 3,626 shares during the last quarter. Hudson Bay Capital Management LP boosted its stake in shares of Agios Pharmaceuticals by 3.8% in the 3rd quarter. Hudson Bay Capital Management LP now owns 270,000 shares of the biopharmaceutical company’s stock valued at $6,682,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Agios Pharmaceuticals by 478.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 50,504 shares of the biopharmaceutical company’s stock valued at $1,125,000 after purchasing an additional 41,768 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.